minalrestat has been researched along with tolrestat in 4 studies
| Studies (minalrestat) | Trials (minalrestat) | Recent Studies (post-2010) (minalrestat) | Studies (tolrestat) | Trials (tolrestat) | Recent Studies (post-2010) (tolrestat) |
|---|---|---|---|---|---|
| 9 | 0 | 1 | 198 | 25 | 14 |
| Protein | Taxonomy | minalrestat (IC50) | tolrestat (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 0.0244 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.2689 | |
| Aldo-keto reductase family 1 member A1 | Homo sapiens (human) | 1.1533 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 0.2303 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.096 | |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 0.043 | |
| Aldo-keto reductase family 1 member A1 | Sus scrofa (pig) | 1.365 | |
| Aldo-keto reductase family 1 member A1 | Rattus norvegicus (Norway rat) | 1.21 | |
| Aldo-keto reductase family 1 member B1 | Sus scrofa (pig) | 0.0225 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hohman, TC; Malamas, MS; Millen, J | 1 |
| Dhagat, U; El-Kabbani, O; Endo, S; Hara, A | 1 |
| Carbone, V; Chung, R; El-Kabbani, O; Endo, S; Hara, A; Zhao, HT | 1 |
| El-Kabbani, O; Endo, S; Hara, A; Kitade, Y; Kuwata, K; Matsunaga, T; Zhao, HT | 1 |
4 other study(ies) available for minalrestat and tolrestat
| Article | Year |
|---|---|
Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Cattle; Diabetes Mellitus, Experimental; Dogs; Drug Evaluation, Preclinical; Erythrocytes; Galactitol; Galactosemias; Glyceraldehyde; In Vitro Techniques; Isoquinolines; Lens, Crystalline; Male; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Spiro Compounds; Stereoisomerism | 1994 |
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldehyde Reductase; Animals; Binding Sites; Enzyme Inhibitors; Mice; Models, Molecular; Protein Binding; Substrate Specificity | 2008 |
Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
Topics: Aldehyde Reductase; Animals; Catalytic Domain; Chlorobenzoates; Computer Simulation; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Imides; Inhibitory Concentration 50; Kinetics; Models, Molecular; Naphthalenes; Quercetin; Quinolones; Recombinant Proteins; Salicylates; Structure-Activity Relationship; Swine; Thermodynamics | 2009 |
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Topics: Aldehyde Reductase; Aldehydes; Aldo-Keto Reductases; Antineoplastic Agents; Benzopyrans; Biomarkers, Tumor; Catalytic Domain; Computer Simulation; Databases, Factual; Drug Discovery; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesol; HeLa Cells; Humans; Kinetics; Models, Molecular; Protein Binding; Recombinant Proteins; Substrate Specificity | 2010 |